Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | STAMBP | O95630 | 1/20 | 0.37 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28285907 | 0.85 | NNMT (0.41) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL30478243 | 0.85 | NNMT (0.41) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL840723 | 0.80 | NNMT (0.36) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL30617860 | 0.75 | HPGDS (0.36) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL2397267 | 0.75 | NNMT (0.44) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL2219734 | 0.73 | NNMT (0.46) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL1503082 | 0.72 | HPGDS (0.51) | NNMTHPGDSCHEK2MKNK1MAP4K4 | |
| Hydrochloric Acid SCHEMBL28641941 | 0.72 | NNMT (0.44) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL27858247 | 0.70 | CYP19A1 (0.47) | CHEK2KDM4E | |
| SCHEMBL7720516 | 0.68 | NNMT (0.41) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300433-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | Ambrilia Biopharma Inc. (CA) | 2011-03-30 | — | — | EP | claimed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | claimed |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2024-03-19 | — | — | US | disclosed |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | Montréal Heart Institute (CA) | 2023-03-23 | — | — | US | disclosed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| EP-2300433-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | Ambrilia Biopharma Inc. (CA) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | PNPO, CCNB1, BLVRB | NNMT 483/4885SMN1; SMN2 3503/4885PSMD14 3798/4885 |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | NNMT 2444/4885SMN1; SMN2 3911/4885PSMD14 4274/4885 |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | NNMT 2444/4885SMN1; SMN2 3911/4885PSMD14 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.